TailorDose®-CPA: Personalized cyclophosphamide cancer treatment
| Reference number | |
| Coordinator | Karolinska Institutet Innovations AB |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | December 2014 - December 2018 |
| Status | Completed |
Purpose and goal
We have employed the companies patented technology for analyses of adducts in the field of breast cancer and can provide a simple method for measurement of active dose in patients receiving EC-treatment. Our method is currently evaluated in a clinical study as a first step towards providing personalised dose adjustment of cytostatic drugs.
Expected results and effects
We now have a validated analytical and pharmacokinetic method for measuring Cyclophosfamid and Epirubicin in breast cancer patients. We have started an ongoing clinical study to validate the methodology in vivo, and while the cohort that has been analysed looks promising, a statistically significant number of patients is still not included.
Planned approach and implementation
We aimed at validating our method statistically in vivo through a clinical trial in collaboration with KI. In retrospect our time line was optimistic which has given us plenty of opportunity to learn from the obstacles that paved the way to actual analyses of patient data. Our improved insight into the chain of logistics has led to a revised business model as well as new business opportunities.